HuidaGene Therapeutics

Food insecurity and quality, compounded by global warming, are a threat to the world. Here, we have partnered with NovoCrops using our CRISPR technology beyond biomedicines to develop climate-resilient crops and CRISPR-assisted crop improvement in breeding strategies. #CRISPR #GeneEditing #Crops #technology #innovation #globalwarming #climiatechanges #agriculture #biotechnology #cropscience #farming https://lnkd.in/gkwdiGCQ

Due to the high demand inquiring about our novel engineered AAV carrying mRNA (RAAV) for transient expression of the functional protein after our oral presentation at the American Society of Gene & Cell Therapy Annual Meeting in May, we have now posted online at bioRxiv & medRxiv. For additional information or the most recent data on RAAV, please contact our Head of International Business Development, Xixi Zhu, or our CEO, Dr. Alvin L.. #GeneTherapy #GeneEditing #AAV #mRNA #biotechnology #technology #innovation #novel #medicine #science #pharmaceuticals https://lnkd.in/emDhJARd

With our recent partnered licensing agreement news with Synthego Corporation on the next-generation CRISPR high-fidelity Cas12Max (hfCas12Max) nuclease, it all started with a casual colleague-colleague conversation. Are you looking to collaborate? Our CEO, Alvin L., and Sr. Director of International Business Development, Xixi Zhu, will be at #BIO2024 , organized by the Biotechnology Innovation Organization, June 3-6, to discuss how, together, we can bring transformative therapies to patients worldwide. Don't get to schedule a 1on1 discussion with Xixi Zhu. #genetherapy #geneediting #CRISPR #genomemedicine #biotechnology #innovation #medicine #pharmaceuticals #licensing #licensingagreement #opportunities #partnerships #collaboration #accessibility #health #scienceandtechnology #technology #healthcare #science #research

📢 Today, HuidaGene Therapeutics and Synthego Corporation announced a partnered licensing agreement on the next-generation CRISPR high-fidelity Cas12Max (hfCas12Max) nuclease. 🎗️ The partnership will complement HuidaGene's HG-PRECISE® platform for CRISPR next-generation nuclease technology and Synthego's advanced CRISPR GMP manufacturing capabilities. We look forward to accelerating access to safe and effective CRISPR solutions to unlock the potential of CRISPR genome medicines. #genetherapy #geneediting #CRISPR #genomemedicine #biotechnology #innovation #medicine #pharmaceuticals #licensing #licensingagreement #opportunities #partnerships #collaboration #accessibility #research https://lnkd.in/e9E4VCRs

Join our Co-founder and CEO, Alvin L., and Sr. Director of Business Development, Xixi Zhu, at #BIO2024 organized by Biotechnology Innovation Organization from June 3-6 in San Diego, where we’ll showcase our #CNS (#ALS , #Alzheimer, #MECP2 Duplication Syndrome ), #neuromuscular (#DMD ), and ophthalmology (#RPE65 #inheritedblindness , #LCA, #maculardegeneration ) pipeline and our proprietary #CRISPR -based HG-PRECISE platform discovering #novel CRISPR #nucleases. We’re excited to connect with you and discuss how we can shape the future of genomic medicine together. Don’t forget to #schedule a one-on-one partnering session with Xixi Zhu in advance to discuss potential #partnerships or #collaborations. #genetherapy #geneediting #genomeediting #Alzhiemer #AlzheimersResearch #Dementia #MECP2Dup #AmyotrophicLateralSclerosis #neuroscience #partnering #collaboration #opportunities #businessdevelopment #biotechnology #pharmacueticals #crossboarder #medicine #innovation

It’s been a very busy week in #Baltimore, but it’s another great #ASGCT #conference in the books! Our HuidaGene Therapeutics ' team is proud to have over 16 presentations this year highlighting our #innovation in AAV #genetherapy , #CRISPR DNA-editing therapy, CRISPR RNA-editing, including our HG-PRECISE platform discovering #novel nucleases and data supporting our 9 #orphandrug or #rare #pediatric disease designations by the U.S. FDA or EMA. Thank you to the American Society of Gene & Cell Therapy conference organizers and all those who attended our 7 oral presentations (CRISPR/Cas13 RNA-editing for #neurodevelopmental #MECP2 duplication syndrome and age-related #maculardegeneration, CRISPR/Cas12Max DNA-editing to target ATXN2 for #ALS , #mRNA -carrying #AAV to transient expressing proteins, #LNP -delivered-Cas12MAX for #hepatitis B, base-editing, and novel deaminase-free base editor) and 9 poster presentations (CRISPR/Cas13 RNA-editing for #Alzheimer and #AngelmanSyndrome, CRISPR/Cas12Max DNA-editing for #Huntington and #DMD, base-editing for DMD, and AAV gene therapy for inherited retinal #blindness). #GeneEditing #biotechnology #pharmaceutical #technology #innovation #ASGCT2024 #science #research #inheritedblindness #AMD #neuroscience #raredisease #medicine #AmyotrophicLateralSclerosis AMYOTROPHIC LATERAL SCLEROSIS Muscular Dystrophy Association MECP2 DUPLICATION FOUNDATION Alzheimer's Association® Huntington's Disease Society of America

The American Society of Gene & Cell Therapy annual meeting in Baltimore, MD, starts in a few hours. Join us at #ASGCT24, where we will showcase our #technology platform (AAV carrying mRNA, LNP delivering our hfCas12Max to target #hepB cccDNA, base editing, and novel deaminase-free base editors) #CRISPR -based #neurology /neuro-myology pre-clinical pipeline, and #ophthalmology clinical and pre-clinical pipeline including data supporting a total of 8 #orphandrug and #rare #pediatricdisease designations last year. Details here on our 16 accepted abstracts, including seven oral talks that will be presented, https://lnkd.in/gKigVvJX #GeneTherapy #GeneEditing #GenomeMedicine #musculardystrophy #blindness #MECP2Duplication #maculardegeneration #biotechnology #science #medicine #BaseEditing #Lebercongenitalamaurosis #AmyotrophicLateralSclerosis #Huntingtondisease #ASGCT

Today HuidaGene Therapeutics announced that the European Medicines Agency (EMA)’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the company’s application of #orphandesignation for HG204, a novel #CRISPR /Cas13Y RNA-editing therapy for the treatment of #MECP2duplication syndrome (MDS). The orphan designation from EMA supplements the ODD and #rare #pediatric disease designation (RPDD) previously granted by the U.S. #FDA in October 2023. #GeneTherapy #GeneEditing #biotechnology #innovation #medicine #CNS #innovation #orphandrug #raredisease https://lnkd.in/ej8Y5vxi

We're pleased to announce that the 'LIGHT" first-in-human trial of HG004 gene replacement therapy for RPE65 mutation-associated inherited retinal disease and HG202 CRISPR RNA-targeting therapy for age-related macular degeneration will be presented in an oral session at #ARVO2024 . The Association for Research in Vision and Ophthalmology (ARVO) annual meeting will be held from May 5 to May 9 in Seattle, Wash. In addition to the two oral presentations, HuidaGene Therapeutics will also present 2 posters. What a great accomplishment for the HuidaGene's team! #VisualSciences #ARVO2024 #genetherapy #CRISPR #GeneEditing #biotechnology #technology #AMD #maculardegeneration #inheritedblindness #blindness #medicine #innovation

We’ll be presenting sixteen abstracts (including 7 oral presentations) and our CEO, Alvin L. , is co-chairing a Neurologic Disease session at the upcoming American Society of Gene & Cell Therapy ‘s 27th Annual Meeting. These data highlights our discovery of new CRISPR technologies to support our robust pipeline in #ophthalmology, #neurology , and #neuromyology advancing in the clinic. #genetherapy #CRISPR #geneediting #CNS #ASGCT24 #science #medicine #biotechnology #innovation https://lnkd.in/gKigVvJX